Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

doi:10.1002/ajh.70069

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

American journal of hematology - 1 Dec 2025

Ru Yuhua, Chen Jia, Ferhat Allain-Thibeault, Labussière-Wallet Hélène, Gedde-Dahl Tobias, Kröger Nicolaus, Socié Gérard, Yakoub-Agha Ibrahim, Eder Matthias, Mielke Stephan, Wu Depei, Mohty Mohamad, Ciceri Fabio, Gorin Norbert-Claude

Abstract excerpt

Given the dismal prognosis for patients with TP53-mutated acute myeloid leukemia (AML), the optimal donor for those undergoing allogeneic hematopoietic cell transplantation (allo-HCT) remains unclear. We retrospectively analyzed adult patients with TP53-mutated AML who underwent first allo-HCT in CR1 between 2010 and 2021. Outcomes were compared among using a haploidentical donor (Haplo), a matched sibling donor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Graft vs Host Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Remission Induction

Share to Siblings

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Share to Unrelated Donors

Source

Open in PubMed Open full text

Identifiers

PMID: 40927841
DOI: 10.1002/ajh.70069
PMCID: PMC12603881

Genes

TP53
NRM
CR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.PMID 40927841Read ↗

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.Semantic proximity Read ↗

Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.Semantic proximity Read ↗

Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome.Semantic proximity Read ↗

Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center studySemantic proximity Read ↗

The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations.Semantic proximity Read ↗

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.Semantic proximity Read ↗

HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable or intermediate risk acute myeloid leukemiaSemantic proximity Read ↗

Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.Semantic proximity Read ↗

Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.Semantic proximity Read ↗

Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWPSemantic proximity Read ↗

Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.Semantic proximity Read ↗

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.